An open-label phase I/II study of carfilzomib, bendamustine and dexamethasone (CBD) in newly diagnosed multiple myeloma patients

Authors
Category Primary study
JournalBlood
Year 2017
This article has no abstract
Epistemonikos ID: e1c3cd8947a6860c981e50e5736c19dddc1e2fd5
First added on: Feb 08, 2025